A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Active, not recruiting · NCT06148636 · Registry updated 2025-11-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors | Adenoma, Islet Cell, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, adenoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine neoplasm, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Early phase 1 | 2025-11-04 | NCT06148636 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| David Bushnell | 2 |
| Holden Comprehensive Cancer Center | 8 |
| National Cancer Institute (NCI) | 3015 |
| Perspective Therapeutics | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Holden Comprehensive Cancer Center at the University of Iowa | Iowa City | United States | 2 |